Biologic Specimen and Data Repository Information Coordinating Center

Biorepository COVID-19 Resources

In collaboration with the NHLBI Biorepository and the Trans-NIH AgingResearchBiobank Steering Committee, NHLBI has developed COVID-19 Biorepository FAQs to serve as a resource/reference for the scientific community. This includes descriptions of enhanced procedures employed by the Biorepository to ensure staff safety and to mitigate the potential of airborne exposure to COVID-19 virus particles, as well as references to CDC shipping guidelines for suspected and confirmed SARS-CoV-2 patient specimens, cultures, or isolates. Click here to access this FAQ document.

NHLBI Cure Sickle Cell Initiative

The NHLBI Cure Sickle Cell Initiative has established a web-based publicly available Metadata Catalog of curated data elements and study documentation from past and current studies of sickle cell disease populations. The catalog has over 10,000 data variables from 16 studies organized into searchable categories. Tools to help investigators find data elements and determine the availability of common data for cross-study analysis are provided. Visit the catalog at https://curesicklecell.rti.org/.

AsthmaNet Biospecimens Available

DNA and plasma biospecimens from 5 AsthmaNet studies are now available for request.

This includes the AsthmaNet Proof of Concept Study of Alendronate for Asthma (ALFA), AsthmaNet Azithromycin for Preventing the Development of Upper Respiratory Tract Illness Into Lower Respiratory Tract Symptoms in Children (APRIL) and Oral Corticosteroids for Treating Episodes of Significant Lower Respiratory Tract Symptoms in Children (OCELOT), AsthmaNet Individualized Therapy For Asthma in Toddlers (INFANT) and Acetaminophen Versus Ibuprofen in Children With Asthma (AVICA), AsthmaNet Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment, and AsthmaNet Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS) studies.

PETAL-ROSE Biospecimens Available

Biospecimens from the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network – Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) study are now available for request.

Funding Opportunity: NHLBI R21 RFA-HL-23-018

This funding opportunity is to support meritorious exploratory research relevant to the NHLBI mission using the biospecimen collections that are stored in the NHLBI Biorepository and that are available through BioLINCC. The first application due date is June 21, 2022.

For more information on RFA-HL-23-018 please visit: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-018.html

as well as the FAQs: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/RFA-HL-23-018